Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Completed · Phase 3

Conditions studied: Kidney Transplantation, Graft Rejection

In brief

The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.

Key facts

Study ID

NCT00251004

Run by

Novartis

People needed

833

Starts

2005-10-01

Expected to finish

2009-10-01

Last updated by the study team

2011-05-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients of any race between 18 to 70 years old (inclusive)
• Patients who gave written informed consent to participate in the study

You may not qualify if…

• Recipients of multi-organ transplantation
• Recipients of a primary cadaveric or primary non-human leucocyte antigen (HLA) identical living donor kidney transplantation.
• Graft cold ischemia time greater than 40 hours.
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.